Published On: Tue, Dec 31st, 2013

Healthcare Stocks Prospects in 2014: Organovo Holdings Inc (NYSEMKT:ONVO), Eli Lilly & Co. (NYSE:LLY), Arena Pharmaceuticals (NASDAQ:ARNA)

Shares of Organovo Holdings Inc (NYSEMKT:ONVO) after opening at $9.38 reached its day high price of $9.85 and then closed at $9.81 by shares raise 5.71% in last trading session. A bio-printing company based in San Diego is expecting to unveil the world’s first printed organ a human liver by next year.

CURRENT ANALYSTS RATING: In last month recommendation trend, 0 analysts that rate its stock at “buy,” 0 analysts rate it a “sell” security. While the mean recommendation of this week is 3.0, {(Strong Buy) 1.0 – 5.0 (Sell)} as compare to last week recommendation of 3.0, which denotes zero change in recommendations.

Eli Lilly & Co. (NYSE:LLY) slump -0.16% in last session as it has a market cap of $57.65B with outstanding shares of 1.08B. The firm plans to hosts Earnings Conference Call  at 9:00AM EST on Jan 30, 2014. Eli Lilly and Company discovers, develops, manufactures, and sells products, in one business segment, pharmaceutical products.

AVERAGE ANTICIPATES: For fourth quarter of 2013, the consensus average estimates of street for the revenue are 5.74B, while experts predict 5.68B revenues for the first quarter of 2014. The firm sales growth (year/est) is calculated 5.40% in Current Qtr. (Dec 13) and for first quarter 2014 was predicted -4.70%.

A biopharmaceutical company Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) performed not well, shares lost at -2.16% on volume of 3,284,377 shares. The stock settled at $5.88 after floating in a range of $5.80 to $6.03. Arena will commence 2014 with brighter potentials. Its anti-obesity pill, Belviq, is now recognized in the marketplace as well as that experience could provide this equity a nice running start going into the new-year. As with just about anything in life, the story here simply comes down to timing.

INSIDE FACTS: As firm has the market capitalization of $1.29B, enterprise value of $1.09B. The company has the price over sales value of $17.10 whereas its price over book value of $11.72 for the most recent quarter. The firm has the total of cash of $180.70M as compares to total debt of $65.54 for the most recent quarter with the current ratio of 7.20 for the most recent quarter.


This content does not and shall not constitute an offer to sell or the solicitation of an offer to buy any of the company’s stocks or securities. As well nor shall there be any sale of the company’s securities in any state or jurisdiction in which such offer, solicitation or sale would be illegal prior to registration or qualification under the securities laws of any such state or jurisdiction. only provide news and information about stocks with intentions that it may be helpful  for investor to take investment decision on their own risk. It is “RECOMMENDED” at all times do your own due diligence; along with consult your financial advisor.

Leave a comment

XHTML: You can use these html tags: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>